Outsourcing in Clinical Trials Southern California 201423-24 September 2014, La Jolla, CA
Following multiple requests from our regular attendees at our other Outsourcing Clinical Trials events, we were very pleased to bring the OCT series to Southern California for the first time in 2013. The event was a huge success, with over 200 pharmaceutical, biotechnology and medical device professionals attending, and we’re now building a bigger and better event for 2014.
Leaders within the industry attend our OCT events to learn from case-study based presentations, network with their peers, discover new solutions and services and find answers to all of their clinical challenges. This event is unique as it caters individually to 3 company types (biotech/pharma, virtual, medical device) with specific content on all aspects of clinical outsourcing: from informed sourcing and efficient contract negotiation through to effective management, monitoring and communication techniques. The agenda boasts presentations, case studies, panel discussions and roundtables all presented and facilitated by a high calibre speaking faculty local to this industry hub.
Whether you are a senior professional in a global pharmaceutical company or a smaller company looking to expand, access to insight and knowledge about the latest pharmaceutical trends is vital.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within biotechnology, pharmaceutical, virtual and medical device companies throughout Southern California.
Outsourcing in Clinical Trials Southern California boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
AbbVie, the development partner of Enanta Pharmaceuticals for protease inhibitors for hepatitis C virus (HCV), has started a Phase IIb clinical trial with Enanta’s next-generation protease inhibitor ABT-493.
US-based biopharmaceutical firm PTC Therapeutics has completed patient enrolment in ACT DMD, the Phase III confirmatory trial of Translarna (ataluren) to treat nonsense mutation Duchenne muscular dystrophy (nmDMD).
US-based pharmaceutical firm Lipocine has dosed the first patient in a Phase I trial of LPCN 1107, an oral hydroxyprogesterone caproate (HPC) product candidate, for preventing preterm birth in pregnant women.
US-based biopharmaceutical firm CytRx has started patient enrolment in an open-label Phase Ib clinical trial of aldoxorubicin plus ifosfamide/mesna as a first-line treatment in subjects with various sarcomas.
Mundipharma has reported results from a randomised, multicentre, Phase III trial of flutiform, a combination of fluticasone propionate and formoterol in a single pressurised metered dose inhaler, to treat paediatric asthma.
Boehringer Ingelheim Pharmaceuticals has reported data from the pivotal Phase III TONADO I and II trials (NCT01431274/NCT01431287) for the fixed-dose combination (FDC) of tiotropium, plus olodaterol to treat patients with moderate to very severe chr…